The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality

Medicine (United States)

Volumn 95, Issue 6, 2016, Pages

  Chiang, Chien Hsieh ^a,b,c   Lu, Chia Wen ^b   Han, Hsieh Cheng ^b,c   Hung, Shou Hung ^a,b,c   Lee, Yi Hsuan ^a,d   Yang, Kuen Cheh ^a,b,c,e   Huang, Kuo Chin ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER MORTALITY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; SMOKING HABIT; ADVERSE EFFECTS; COMPLICATION; DIABETIC COMPLICATION; LIVER TUMOR; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION;

EID: 84958260566     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002699     Document Type: Article

References (52)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365: 1118-1127.
2. Liao SF, Yang HI, Lee MH, et al. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11, 801 men in Taiwan. PLoS One. 2012; 7: e34779.
3. Wen CP, Lin J, Yang YC, et al. Hepatocellular carcinoma risk prediction model for the general population: The predictive power of transaminases. J Natl Cancer Inst. 2012; 104: 1599-1611.
4. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan. Gastroenterology. 2008; 135: 111-121.
5. Inoue M, Kurahashi N, Iwasaki M, et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: A large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 2009; 20: 741-750.
6. Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006; 43: 1295-1302.
7. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut. 2005; 54: 533-539.
8. Brower V. Illuminating the diabetes-cancer link. J Natl Cancer Inst. 2012; 104: 1048-1050.
9. Chiang CH, Huang KC. Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol. 2014; 20: 7213-7216.
10. Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: A systematic review and meta-Analysis. Diabetes Metab Res Rev. 2012; 28: 109-122.
11. Chiang CH, Lee LT, Hung SH, et al. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-Aged and elderly. Hepatology. 2014; 59: 2207-2215.
12. Chen J, Han Y, Xu C, et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: A metaanalysis of cohort studies. Eur J C Prev. 2015; 24: 89-99.
13. Shau WY, Shao YY, Yeh YC, et al. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist. 2012; 17: 856-862.
14. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009; 49: S72-84.
15. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
16. Wang LY, You SL, Lu SN, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: A cohort of 2416 HBsAg-seropositive and 9421 HBsAgseronegative male residents in Taiwan. Cancer Causes Control. 2003; 14: 241-250.
17. Tseng CH. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: A 12-year follow-up of a national cohort in Taiwan. Hepatol Int. 2013; 7: 693-702.
18. Ogimoto I, Shibata A, Kurozawa Y, et al. Risk of death due to hepatocellular carcinoma among smokers and ex-smokers. Univariate analysis of JACC study data. Kurume Med J. 2004; 51: 71-81.
19. Siegel AB, Conner K, Wang S, et al. Smoking and hepatocellular carcinoma mortality. Exp Ther Med. 2012; 3: 124-128.
20. Shih WL, Chang HC, Liaw YF, et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer. 2012; 131: 2612-2621.
21. Raffetti E, Portolani N, Molfino S, et al. Role of aetiology, diabetes, tobacco smoking and hypertension in hepatocellular carcinoma survival. Digest Liver Dis. 2015; 47: 950-956.
22. Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013; 309: 1014-1021.
23. Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: Types of miscoding and effects on mortality statistics. Int J Epidemiol. 2000; 29: 336-343.
24. WHO., Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363: 157-163.
25. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2937-2944.
26. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014; 60: 110-117.
27. Liu J, Yang HI, Lee MH, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology. 2014; 60: 77-86.
28. Chien YC, Jan CF, Chiang CJ, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: A 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014; 60: 125-132.
29. Chiang CH, Lai JS, Sheu JC, et al. The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. Obes Res Clin Pract. 2012; 6: e31-e38.
30. Chiang CH, Yang HI, Jen CL, et al. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond). 2013; 37: 410-415.
31. Chiang CH, Lai JS, Hung SH, et al. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring). 2013; 21: 291-296.
32. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012; 55: 948-958.
33. Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010; 46: 744-751.
34. Singh S, Singh PP, Roberts LR, et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014; 11: 45-54.
35. Kowall B, Rathmann W, Strassburger K, et al. Association of passive and active smoking with incident type 2 diabetes mellitus in the elderly population: The KORA S4/F4 cohort study. Eur J Epidemiol. 2010; 25: 393-402.
36. Mozaffarian D, Marfisi R, Levantesi G, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet. 2007; 370: 667-675.
37. Bergman BC, Perreault L, Hunerdosse D, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes. 2012; 61: 3156-3166.
38. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-393.
39. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: A 1-year prospective study. Metabolism. 2011; 60: 1456-1464.
40. Bensellam M, Laybutt DR, Jonas JC, et al. The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol. 2012; 364: 1-27.
41. Morimoto A, Ohno Y, Tatsumi Y, et al. Impact of smoking cessation on incidence of diabetes mellitus among overweight or normalweight Japanese men. Diabetes Res Clin Pract. 2012; 96: 407-413.
42. Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: An important consideration in studies of older adults. J Am Geriatr Soc. 2010; 58: 783-787.
43. Chiang CH, Huang KC. Reply. Hepatology. 2015; 61: 1763-1764.
44. Chiang CH, Ni YH. Obscure clinical implication of occult hepatitis B virus infection by perinatal transmission despite prophylaxis with hepatitis B vaccination and HBIG Letter. J Hepatol. 2012; 57: 1401.
45. Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012; 57: 730-735.
46. Setiawan VW, Wilkens LR, Lu SC, et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015; 148: 118-125quiz e115.
47. Kurozawa Y, Ogimoto I, Shibata A, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer. 2005; 93: 607-610.
48. Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008; 48: 129-136.
49. Sang LX, Chang B, Li XH, et al. Consumption of coffee associated with reduced risk of liver cancer: A meta-Analysis. BMC Gastroenterol. 2013; 13: 34.
50. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35: S64-71.
51. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and metaanalysis. Am J Gastroenterol. 2013; 108: 881-891quiz 892.
52. Marchesini G, Forlani G. Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia. Hepatology. 2012; 55: 1298-1300.